Comparison of Analgesic Efficacy and Safety of Low-Dose Transdermal Fentanyl and Oral Oxycodone in Opioid-Naïve Patients with Cancer Pain
Biological and Pharmaceutical Bulletin · 2023
DOI: 10.1248/bpb.b23-00331 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biological and Pharmaceutical Bulletin, 2023. Verfasst von Mariko Kawana und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Kameda General Hospital. Hauptthemen laut MEDLINE: Cancer Pain, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben.
Abstract (Originalsprache)
In Japan, a low-dose transdermal fentanyl (TDF; 0.5 mg) has been approved to address pain in opioid-naïve patients with cancer; however, efficacy and safety data are lacking. To determine the efficacy and safety of TDF, patients with opioid-naïve cancer pain prescribed TDF (0.5 mg/d) and oral oxycodone sustained-release formulation (OXY) 10 mg/d were extracted from electronic medical and nursing records. Overall, 40 and 101 subjects were analyzed in the TDF and OXY groups, respectively. Compared with baseline (median [minimum, maximum]) values, changes in the Numerical Rating Scale (NRS) score on days 1, 3, and 7 post-administration were as follows: TDF (0 [-5, 4]) and OXY (-1.0 [-8, 3]); TDF (-1.5 [-6, 3]) and OXY (-2.0 [-8, 4]); and TDF (-2.0[-6, 3]) and OXY (-3.0[-8, 5]), respectively. No significant difference was observed between the groups on days 1 and 3; however, the change in the NRS on day 7 was significantly higher in the OXY group than that in the TDF group. Regarding adverse events, nausea occurred in 12.5 and 13.9% of patients in the TDF and OXY groups, respectively, while 12.5% of TDF- and 10.9% of OXY-treated patients experienced somnolence, revealing similar occurrence in both groups. However, constipation was more common in the OXY group (TDF: 50.0%, OXY: 71.3%). No serious adverse events (e.g., respiratory depression) were observed in either group. Low-dose TDF (0.5 mg), available only in Japan, showed comparable efficacy and safety to OXY (10 mg/d) and can be a first choice for opioid-naïve patients with cancer pain.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Kameda General Hospital.
- Department of Pharmacy, Tokyo Medical University Hospital.
- Department of Pharmacy, Gifu University Hospital.
- Palliative Care Center, Yao Municipal Hospital.
- Department of Pharmacy, National Hospital Organization Sendai Medical Center.
- Department of Pharmacy, Yaizu City Hospital.
Zitieren
APA
Kawana, M., Miyasato, A., Funato, M., Nagatani, K., Suzuki, N., Onoda, C., Fujimoto, H., Ohno, R., Kusakabe, A., Kiribayashi, M., Nakamura, K., Kondo, M., Ozeki, A., Okamoto, K., & Kokubun, H. (2023). Comparison of Analgesic Efficacy and Safety of Low-Dose Transdermal Fentanyl and Oral Oxycodone in Opioid-Naïve Patients with Cancer Pain. Biological and Pharmaceutical Bulletin. https://doi.org/10.1248/bpb.b23-00331
Vancouver
Kawana M, Miyasato A, Funato M, Nagatani K, Suzuki N, Onoda C, et al. Comparison of Analgesic Efficacy and Safety of Low-Dose Transdermal Fentanyl and Oral Oxycodone in Opioid-Naïve Patients with Cancer Pain. Biological and Pharmaceutical Bulletin. 2023. doi:10.1248/bpb.b23-00331
BibTeX
@article{Kawana2023,
author = {Kawana, Mariko and Miyasato, Akime and Funato, Miyui and Nagatani, Keigo and Suzuki, Norifumi and Onoda, Chiharu and Fujimoto, Hidenori and Ohno, Rintaro and Kusakabe, Ayuko and Kiribayashi, Mio and Nakamura, Kazuyo and Kondo, Masayoshi and Ozeki, Ayumi and Okamoto, Kousuke and Kokubun, Hideya},
title = {Comparison of Analgesic Efficacy and Safety of Low-Dose Transdermal Fentanyl and Oral Oxycodone in Opioid-Naïve Patients with Cancer Pain},
journal = {Biological and Pharmaceutical Bulletin},
year = {2023},
doi = {10.1248/bpb.b23-00331}
}
EUVIMED